colchicine + diltiazem ER

Colchicine + diltiazem ER refers to the *co-administration* of colchicine (commonly used to treat and prevent gout and certain autoinflammatory conditions) and extended-release diltiazem (a calcium channel blocker primarily used for hypertension, angina, and some arrhythmias). There is no unique branded combination product; this regimen describes the concurrent use of these two agents. Colchicine is a microtubule polymerization inhibitor that acts by binding to tubulin, thus disrupting cellular functions such as neutrophil migration and activity, leading to its anti-inflammatory effects. Diltiazem ER inhibits L-type calcium channels in the heart and blood vessels, producing anti-anginal and antihypertensive effects. Diltiazem ER is also a potent inhibitor of both cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp), enzymes and transporters responsible for colchicine metabolism and transport. Their co-administration results in decreased clearance and increased plasma levels of colchicine, necessitating careful dose adjustment and/or increased monitoring due to the elevated risk of colchicine toxicity, including life-threatening outcomes such as pancytopenia, multiorgan failure, and cardiac arrhythmias[1][2][4][7].

Other names

colchicine and diltiazem extended-releasecolchicine + diltiazem extended-release